Literature DB >> 28459633

Identification of Human UMP/CMP Kinase 1 as Doxorubicin Binding Target Using Protein Microarray.

Shuxian Chen1, Xu Wang1, Xianghui Ye1, Donghui Ma2,3, Caiwei Chen2,3, Junlong Cai4, Yongfeng Fu4, Xunjia Cheng4, Yun Chen1, Xiaohai Gong1, Jian Jin1.   

Abstract

Doxorubicin (DOX) is a leading anthracycline drug with exceptional efficacy; however, little is known about the molecular mechanisms of its side effects, which include heart muscle damage, noncancerous cell death, and drug resistance. A total of 17,950 human proteins expressed in HEK293 cells were screened and yielded 14 hits. Competitive and binding experiments further verified the binding of DOX to UMP/CMP kinase 1 (CMPK1), and microscale thermophoresis showed that DOX binds to CMPK1 with a Kd of 1216 nM. In addition, we observed that the binding of DOX to CMPK1 activated the phosphorylation of CMP, dCMP, and UMP. A significant activation was observed at the concentration of 30 µM DOX and reached plateau at the concentration of DOX 30 µM, 150 µM, and 100 µM, respectively. DOX would add up stimulation of CMPK1 by DTT and overcome inhibition of CMPK1 by NaF, EDTA. In summary, we showed that DOX might bind to the nonactive site of CMPK1 and regulate its activity with magnesium.

Entities:  

Keywords:  UMP/CMP kinase; biotinylated drug; doxorubicin; high throughput; microarray

Mesh:

Substances:

Year:  2017        PMID: 28459633     DOI: 10.1177/2472555217707704

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  2 in total

Review 1.  Role of pH in Regulating Cancer Pyrimidine Synthesis.

Authors:  Saad Saeed Alqahtani; Tomas Koltai; Muntaser E Ibrahim; Adil H H Bashir; Sari T S Alhoufie; Samrein B M Ahmed; Daria Di Molfetta; Tiago M A Carvalho; Rosa Angela Cardone; Stephan Joel Reshkin; Abdelhameed Hifny; Mohamed E Ahmed; Khalid Omer Alfarouk
Journal:  J Xenobiot       Date:  2022-07-06

2.  Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells.

Authors:  Xu Wang; Renjie Hui; Yun Chen; Wentao Wang; Yujiao Chen; Xiaohai Gong; Jian Jin
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.